ARID1A loss of function is quite common, mostly among gynecological cancers, and renders the ATR pathway indispensable for ARID1A-deficient cells, as demonstrated in vitro and ex vivo in colorectal cancer (CRC) cells [114,115]. Here, ARID1A is linked to female reproductive organ cancer.